Liver Cancer Market Expected to Accelerate Significantly Over Forecast Period (2022-32) – DelveInsight Estimates | H3 Biomedicine, Genoscience Pharma, Kymab Limited, Exelixis

Delveinsight Business Research LLP

According to DelveInsight’s assessment, liver cancer market dynamics are expected to transform in the coming years due to the launch of emerging therapies, rising incidence of liver cancer in 7MM, research and development activities (R&D) in progress and the active participation of the world’s giants of pharma and biotechnology in the therapeutic segment.

by DelveInsight”Liver Cancer Market Overview, Epidemiology and Market Forecast 2032“The report provides an in-depth understanding of the disease, historical and forecasted epidemiology, and liver cancer market size, share, and trends across the seven major (7MM) markets (i.e.- i.e. USA, EU5 (Germany, Spain, Italy, France and UK) and Japan).

The Liver Cancer Market report covers emerging drugs, current treatment practices, individual therapies market share, and current and forecasted market size from 2019 to 2032. It also assesses the practice/algorithm of current treatment, key drivers and barriers impacting market growth, and unmet medical needs to select the best opportunities and assess the underlying potential of the market.

liver cancer market

Liver cancer: an overview

Liver cancer is defined as a liver tumor not eligible for local therapies given the extent of the disease or liver tumors that recur after local therapies. Patients with liver cancer usually have significant underlying liver disease, which is associated with poor tolerance to systemic chemotherapy.

The cancer may have spread to nearby lymph nodes and distant sites in the body. Liver cancer does not often metastasize, but when it does it is more likely to spread to the lungs and bones. These cancers are widespread, they cannot be removed by surgery

Liver Cancer Market Highlights

  • According to the National Cancer Institute, the combination treatment worked better than sorafenib. More people treated with the combination than with sorafenib were still alive after 1 year: 67% in the combination group and 55% in the sorafenib group.

  • According to the World Cancer Watch UK, the ASR incidence rate for liver cancer is 5.3/100,000, which is estimated to be around 8,156 new cases diagnosed in 2020, and the mortality rate Liver cancer ASR is 4.1/100,000 which is estimated to be around 7,061 deaths in 2020.

  • According to DelveInsight, the dynamics of the liver cancer market are expected to change in the coming years owing to the rising healthcare expenditures across the world and the active participation of pharmaceutical giants in the therapeutic segment.

  • Globally, some of the major players, such as H3 Biomedicine, Genoscience Pharma, Kymab Limited, and others are actively working to develop drugs for the treatment of liver cancer. The planned launch of emerging therapies will change the treatment landscape in the years to come.

liver cancer market

The market outlook section of the report helps in building a detailed understanding of the historical, current and forecasted. Liver Cancer Market Size by analyzing the impact of current and emerging therapies. It also provides an in-depth assessment of market drivers and barriers, unmet needs, and emerging technologies that are likely to impact market dynamics.

The report gives full details of Liver Cancer Market Trend for each marketed drug and mid- and late-stage therapies by assessing their impact based on annual therapy cost, mechanism of action (MoA), route of administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Epidemiological evaluation of liver cancer

The epidemiology section provides an overview of historical, current and projected epidemiological trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and projected epidemiological trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of the diagnosed and prevalent patient pool, future trends and views of key opinion leaders.

Segmentation of liver cancer epidemiology

  • Total incidence of liver cancer cases

  • Total treated cases of liver cancer

  • Patients by stage of liver cancer

Liver cancer drug pipeline development and adoption activities

The drug absorption section focuses on the absorption rate of potential drugs recently launched in the liver cancer market or should be launched during the study period. The analysis covers liver cancer market uptake by drugs, patient uptake of therapies, and sales of each drug.

In addition, the therapeutic evaluation section helps to understand which drugs are absorbed the fastest and the reasons for the maximum use of drugs. Moreover, it compares drugs based on their market share.

The report also covers the Liver Cancer Pipeline Development Activities. It provides valuable information on different therapeutic candidates at various stages and on the main companies involved in the development of targeted therapies. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details and other information on emerging therapies.

Find out how the liver cancer market will evolve by 2032 @

Some of the Major Companies in the Liver Cancer Therapeutics Market Include:

  • H3 Biomedicine Inc.

  • Genoscience Pharma

  • Kymab Limited

  • Exelixis

And much more

Liver cancer therapies covered in the report include:

  • H3B-6527

  • GNS561

  • KY1044

  • Cabozantinib

And many more

Other emerging drugs and key companies are covered in the report. Download the sample PDF to learn more @

Table of Contents (TOC)

1. Key information

2. Executive Summary

3. Liver Cancer Competitive Intelligence Analysis

4. Liver Cancer Market Overview at a Glance

5. Liver Cancer Disease Background and Overview

6. Liver Cancer Patient Journey

7. Liver cancer epidemiology and patient population (in USA, EU5 and Japan)

8. Liver cancer treatment algorithm, current treatment and medical practices

9. Liver Cancer Unmet Needs

10. Key Parameters of Liver Cancer Treatment

11. Products marketed against liver cancer

12. Emerging Liver Cancer Drugs and Latest Therapeutic Advances

13. Liver Cancer Key Seven Market Analysis

14. Attribute analysis

15. Liver Cancer Market Outlook (in US, EU5 & Japan)

16. Liver Cancer Access and Reimbursement Overview

17. KOL Views on Liver Cancer Market

18. Liver Cancer Market Drivers

19. Liver Cancer Market Barriers

20. Appendix

21. DelveInsight Abilities

22. Disclaimer

*The table of contents (TOC) is not exhaustive; final content may vary. Refer to the sample report for the complete table of contents.

Download a sample PDF to explore the report’s top offerings @

Related Reports by DelveInsight

Liver Cancer Pipeline Overview, 2022

by DelveInsight”Liver Cancer Pipeline Overview” report provides comprehensive information about 75+ companies and 75+ drugs in the liver cancer pipeline landscape. It covers pipeline drug profiles, including clinical and non-clinical stage products. It also covers therapeutic evaluation by product type, stage, route of administration and molecule type. It further highlights inactive pipeline products in this space.

About DelveInsight
DelveInsight is a leading business consultant and market research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing complete end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact person: Shruti Thakur
E-mail: Send an email
Call: 09650213330
Address:304 S. Jones Boulevard #2432
Town: Vegas
State: NV
Country: United States

Comments are closed.